Document Detail


Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy.
MedLine Citation:
PMID:  8355075     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We evaluated alterations of substrate utilization in a rat model of adriamycin cardiomyopathy with deteriorating left ventricular function. Rats were treated with adriamycin (2 mg/kg), once a week for 6, 8, 9 and 10 wk. Fluorine-18-F-deoxyglucose (18F-FDG) and 125I-beta-methyl-branched fatty acid (125I-BMIPP) were used as tracers of glucose and fatty acid metabolism and 99mTc-hexakis (2-methoxyisobutyl-isonitrile) (99mTc-MIBI) was used as a myocardial blood flow tracer. Left ventricular ejection fraction (LVEF) calculated from gated blood pool images was used as an indicator of cardiac function. LVEF was normal in the 6-wk group (78.0% +/- 4.8%), abruptly decreased in the 8-wk group (43.1% +/- 10.1%) and further deteriorated in the 9-wk group (27.6% +/- 13.4%). Accumulation of 18F-FDG (%kgID/g) in the hearts of adriamycin treated animals progressively decreased compared to controls (2.19% +/- 0.38%); 1.47% +/- 0.42% (p < 0.01) at 6 wk, 1.22% +/- 0.27% (p < 0.001) at 8 wk, 0.69% +/- 0.56% (p < 0.001) at 9 wk and 0.50% +/- 0.08% (p < 0.001) at 10 wk. This decrease occurred earlier than the deterioration in LVEF. Myocardial accumulation of 125I-BMIPP decreased in the advanced stages of adriamycin cardiomyopathy and was well correlated with the decrease in 18F-FDG accumulation. However, the decrease was less profound than for 18F-FDG; 53.7% +/- 9.8% versus 31.6% +/- 25.4% of control at 9 wk (p = NS), 49.5% +/- 15.3% versus 22.6% +/- 3.5% of control at 10 wk (p < 0.05). Accumulation of 99mTc-MIBI did not differ between controls and the adriamycin treated groups. There were no differences in blood glucose levels between controls and adriamycin treatment groups. Both glucose and fatty acid utilization are decreased in adriamycin-induced cardiomyopathy and these critical impairments in energy metabolism are associated with heart failure. Impaired myocardial glucose utilization measured with 18F-FDG may be a particularly sensitive marker of adriamycin cardiomyopathy.
Authors:
S Wakasugi; A J Fischman; J W Babich; R J Callahan; D R Elmaleh; R Wilkinson; H W Strauss
Related Documents :
11525115 - Arrhythmogenic right ventricular dysplasia presenting as regression of left ventricular...
6230525 - Importance of morpho-clinical correlations in the diagnosis of congestive cardiomyopath...
17368585 - Hypertrophic cardiomyopathy mimicking acute myocardial infarction: diagnostic role of c...
11276095 - Advances in human cardiac 31p-mr spectroscopy: sloop and clinical applications.
10149265 - Cardiac ultrasound: its role in the recognition and management of fetal heart disease.
24707265 - Lacunar infarction associated with anabolic steroids and polycythemia: a case report.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  34     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  1993 Sep 
Date Detail:
Created Date:  1993-09-23     Completed Date:  1993-09-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1529-35     Citation Subset:  IM    
Affiliation:
Department of Radiology, Massachusetts General Hospital, Boston 02114.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Deoxyglucose / analogs & derivatives,  diagnostic use
Doxorubicin / adverse effects*
Fatty Acids*
Fluorine Radioisotopes / diagnostic use
Fluorodeoxyglucose F18
Gated Blood-Pool Imaging
Heart / radionuclide imaging*
Heart Failure / chemically induced*,  radionuclide imaging*
Iodine Radioisotopes / diagnostic use
Iodobenzenes / diagnostic use
Male
Myocardium / metabolism*
Rats
Rats, Wistar
Technetium Tc 99m Sestamibi / diagnostic use
Ventricular Function, Left / drug effects*
Chemical
Reg. No./Substance:
0/Fatty Acids; 0/Fluorine Radioisotopes; 0/Iodine Radioisotopes; 0/Iodobenzenes; 109581-73-9/Technetium Tc 99m Sestamibi; 116754-87-1/iodofiltic acid; 154-17-6/Deoxyglucose; 23214-92-8/Doxorubicin; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Load independence of early diastolic filling parameters in the anesthetized canine model.
Next Document:  A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to stre...